Thus it is good news. It is a small island of sanity -- recalling a more rational time in medicine, and pandemic abatement in the US. Here's the story from this morning:
. . .Danish drugmaker Bavarian Nordic announced today that the US government has placed a $144 million order for a freeze-dried version of its mpox vaccine, which can also be used to prevent smallpox.
The freeze-dried formulation of the Jynneos vaccine was approved by the US Food and Drug Administration (FDA) in March. It will be easier to store and transport, and has a longer shelf life, than the liquid-frozen formulation that Bavarian Nordic has been supplying to the US government since 2010. The company ramped up production of Jynneos in response to the mpox outbreak that began in 2022.
Jynneos was first approved by the FDA in 2019 and is one of two FDA-approved vaccines for the prevention of smallpox and mpox.
The options exercised under Bavarian Nordic's existing contract with the Biomedical Advanced Research and Development Authority (BARDA), which was awarded in 2017, are valued at $143.6 million and will support manufacturing and supply of freeze-dried Jynneos starting in 2026. . . .
Now you know. Onward, resolutely.
नमस्ते
No comments:
Post a Comment